Development
Takeda Pharmaceutical Company Limited
TAK
$15.52
$0.211.37%
NYSE
| 12/31/2023 | 09/30/2023 | 06/30/2023 | 03/31/2023 | 12/31/2022 | |
|---|---|---|---|---|---|
| Revenue | -1.23% | -0.90% | -2.13% | -6.38% | -4.73% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -1.23% | -0.90% | -2.13% | -6.38% | -4.73% |
| Cost of Revenue | -0.24% | -3.15% | -7.68% | -7.95% | -0.76% |
| Gross Profit | -1.68% | 0.16% | 0.54% | -5.67% | -6.49% |
| SG&A Expenses | -1.01% | -2.64% | -3.58% | -6.55% | -9.88% |
| Depreciation & Amortization | 9.10% | 7.70% | -6.57% | -6.99% | -3.79% |
| Other Operating Expenses | -12.44% | 0.37% | -5.11% | -4.32% | 44.80% |
| Total Operating Expenses | 1.40% | 0.43% | -4.61% | -5.93% | -2.04% |
| Operating Income | -19.66% | -10.39% | 15.08% | -8.89% | -20.16% |
| Income Before Tax | -44.11% | -21.54% | 33.45% | 0.87% | -56.06% |
| Income Tax Expenses | -310.08% | -75.23% | 36.55% | -33.44% | -110.12% |
| Earnings from Continuing Operations | -36.59% | -16.10% | 32.91% | 12.03% | -50.45% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -8,691.95% | -132.17% | 71.98% | 84.37% | 100.56% |
| Net Income | -36.63% | -16.13% | 32.95% | 12.07% | -50.43% |
| EBIT | -19.66% | -10.39% | 15.08% | -8.89% | -20.16% |
| EBITDA | -8.43% | -4.80% | 5.56% | -6.99% | -12.06% |
| EPS Basic | -37.01% | -16.08% | 33.27% | 13.23% | -49.97% |
| Normalized Basic EPS | -35.42% | -18.83% | 20.57% | 3.67% | -22.45% |
| EPS Diluted | -37.08% | -16.30% | 33.07% | 13.12% | -50.05% |
| Normalized Diluted EPS | -35.40% | -18.94% | 20.53% | 3.69% | -22.52% |
| Average Basic Shares Outstanding | 0.60% | 0.20% | -0.32% | -0.77% | -0.94% |
| Average Diluted Shares Outstanding | 0.45% | 0.14% | -0.15% | -0.64% | -0.98% |
| Dividend Per Share | -6.68% | -6.68% | -16.35% | -16.35% | -14.44% |
| Payout Ratio | 0.54% | 0.03% | -0.35% | -0.27% | 0.66% |